Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.70 +0.35 (+1.05%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements. 
Via InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Recap: GSK Q4 Earnings
Via Benzinga
Earnings Outlook For GSK
Via Benzinga
A Look Into GSK Inc's Price Over Earnings
Via Benzinga
What the Options Market Tells Us About GSK
Via Benzinga
Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option
Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024. 
Via Benzinga
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
What's Going On With GSK Stock Today?
GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired. 
Via Investor's Business Daily
GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine
GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections. 
Via Benzinga
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
From Elegen
Via Business Wire
GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M
GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake. 
Via Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles
Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning 
Via Benzinga
GSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio
GSK plc (NYSE: GSK) has agreed to acquire Aiolos Bio Inc 
Via Benzinga
GSK Enters Agreement to Acquire Aiolos Bio
From Aiolos Bio, Inc.
Via Business Wire
GlaxoSmithKline PLC (NYSE: GSK) Records 52-Week High Monday Morning
Via Investor Brand Network
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Exposures Product Safety
Why Biopharmaceutical Player CureVac Shares Are Rising Today
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday. 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Sleeper Hits: 3 Unexpected Stocks Poised for a Breakout in 2024
Many stocks emerge from Wall Street's doghouse relatively quickly. Here are three names that could become surprise breakout stocks for 2024. 
Via InvestorPlace
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year 
Via Talk Markets
Dell To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.